Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant (AMR) infections …

First variants of the Klebsiella pneumoniae carbapenemase (KPC), KPC-2 and KPC-3, have
encountered a worldwide success, particularly in K. pneumoniae isolates. These beta …

Multidrug resistance (MDR) represents a serious global threat due to the rapid global spread
and limited antimicrobial options for treatment of difficult-to-treat (DTR) infections sustained …

Management of patients with infections caused by multidrug-resistant organisms is
challenging and requires a multidisciplinary approach to achieve successful clinical …

Introduction The choice of best therapeutic strategy for difficult-to-treat resistance (DTR)
Gram-negative infections currently represents an unmet clinical need. Areas covered This …

Hypervirulence and carbapenem-resistant have emerged as two distinct evolutionary
pathotypes of Klebsiella pneumoniae, with both reaching their epidemic success and posing …

Abstract Objectives Carbapenemase-producing Enterobacterales represent a major cause
of difficult-to-treat infections world-wide. Novel β-lactam/β-lactamase inhibitor combinations …

Antimicrobial resistance is a global health threat. Among Gram-negative bacteria, resistance
to carbapenems, a class of β-lactam antibiotics, is usually a proxy for difficult-to-treat …

Bacterial resistance mechanisms are continuously and rapidly evolving. This is particularly
true for Gram-negative bacteria. Over the last decade, the strategy to develop new β …

Carbapenems are considered to be among the last line antibiotics against extended-
spectrum β-lactamase producing Enterobacterales. Carbapenem-resistant Klebsiella …